PARP7 Inhibition Stabilizes STAT1/2 and Relieves EAE in Mice

Study Background and Research Question

Type I interferons (IFN-Is) are central regulators of innate and adaptive immunity, orchestrating responses to pathogens and contributing to the control of cancer and autoimmunity. The fine-tuning of IFN-I signaling is critical: excessive activation may drive autoimmunity, while insufficient signaling impairs host defense. In particular, the JAK-STAT pathway—comprising Janus kinases and the signal transducer and activator of transcription proteins (STAT1/STAT2)—mediates the downstream effects of IFN-Is, leading to the transcription of interferon-stimulated genes (ISGs). Aberrations in this pathway have been implicated in autoimmune conditions such as multiple sclerosis (MS), typically studied in mice via experimental autoimmune encephalomyelitis (EAE) models induced by myelin oligodendrocyte glycoprotein peptide (MOG (35-55)).

While the upstream regulation of IFN-I production is well-characterized, less is known about the post-translational modulation of STAT1/STAT2 and its implications for CNS autoimmunity. The present study by Xu et al. (Cell Reports, 2025) addresses this gap, investigating the role of the mono-ADP-ribosyltransferase PARP7 in STAT1/STAT2 turnover and IFN-I pathway inhibition, and assessing the therapeutic potential of PARP7 inhibition in EAE.

Key Innovation from the Reference Study

The central innovation of the Xu et al. study lies in the identification of a previously unappreciated regulatory axis: PARP7 (also known as TiPARP) directly mono-ADP-ribosylates STAT1 and STAT2, thereby promoting their ubiquitination and degradation via autophagy. This mechanism operates downstream of IFN-I production, distinguishing PARP7 as a suppressor of IFN-I signaling rather than an inhibitor of IFN-I synthesis. Pharmacological or genetic inhibition of PARP7 stabilizes STAT1/STAT2, enhances IFN-I responses, and—crucially—alleviates neurological deficits in the EAE mouse model. These findings delineate a novel checkpoint within the interferon signaling cascade, with direct relevance for autoimmune encephalomyelitis research and the broader field of neuroinflammation assays.

Methods and Experimental Design Insights

To elucidate PARP7's impact on IFN-I signaling and EAE pathology, the authors employed a combination of molecular, cellular, and in vivo approaches:

• Genetic and Pharmacological Manipulation: PARP7 was depleted using CRISPR/Cas9-mediated knockout and inhibited with small-molecule compounds in cell lines and mouse models.
• Protein Interaction and Modification Analysis: Co-immunoprecipitation and immunoblotting demonstrated the physical association between PARP7 and STAT1/STAT2, as well as evidence of ADP-ribosylation and increased ubiquitination of these transcription factors.
• Autophagic Flux Assessment: The study used p62/SQSTM1 recruitment assays and autophagy inhibitors to confirm PARP7-driven degradation of STAT1/2 via the autophagic pathway.
• Transcriptomic and Functional Readouts: Quantitative PCR and reporter assays established the downstream impact on ISG expression.
• EAE Induction and Clinical Scoring: EAE was induced in C57BL/6 mice using the well-established MOG (35-55) peptide protocol, with clinical scores, histopathology, and immune infiltrate analyses performed to gauge disease severity and response to PARP7 inhibition.

By integrating these techniques, the authors robustly linked molecular events to functional outcomes in autoimmune disease modeling.

Core Findings and Why They Matter

The study's pivotal discoveries include:

• PARP7 Targets STAT1/STAT2 for Autophagic Degradation: PARP7 forms cytosolic foci and mono-ADP-ribosylates STAT1/STAT2, marking them for ubiquitination and subsequent p62-mediated autophagic degradation. This reduces the cellular pool of STAT1/2, limiting IFN-I signaling capacity.
• PARP7 Inhibition Restores Interferon Signaling: Genetic or pharmacological PARP7 inhibition stabilizes STAT1/2, resulting in increased ISG expression and enhanced type I interferon responses.
• Amelioration of EAE Symptoms: In the MOG (35-55)-induced EAE model, mice treated with PARP7 inhibitors exhibited reduced neurological deficits and demyelination, as well as diminished immune cell infiltration within the CNS (Xu et al., 2025).

These findings are meaningful for multiple sclerosis research, as they reveal a tractable molecular target that modulates neuroinflammation via the IFN-I pathway. The study's insights may inform the development of PARP7-targeted interventions in preclinical autoimmune disease models and, potentially, future translational applications.

Comparison with Existing Internal Articles

Several internal resources contextualize the role of MOG (35-55) as the gold-standard myelin oligodendrocyte glycoprotein peptide for EAE induction in MS research. For example, the article “MOG (35-55): The Benchmark Peptide for Autoimmune Encephalomyelitis Research” details the immunogenicity and reproducibility of MOG (35-55) for modeling T and B cell responses, essential for dissecting neuroinflammatory pathways. Similarly, “MOG (35-55): Advancing Autoimmune Encephalomyelitis Research” discusses robust protocols and troubleshooting insights, which align with the rigorous EAE induction techniques employed by Xu et al.

Notably, “Unlocking Translational Potential: MOG (35-55) Peptide as...” bridges recent advances in interferon pathway research with practical workflow recommendations, highlighting the emerging significance of STAT1/2 regulation and PARP7 inhibition in refining EAE models. The present reference study further validates these trends, providing mechanistic clarity and preclinical evidence for targeting PARP7 in neuroinflammation assays.

Limitations and Transferability

While the results are compelling, several limitations merit consideration:

• Model-Specific Constraints: The findings are based on the C57BL/6 mouse EAE model using MOG (35-55), which, although widely accepted, does not capture all aspects of human MS heterogeneity.
• Pharmacological Specificity: Off-target effects of PARP7 inhibitors and compensatory changes in related pathways were not exhaustively examined.
• Translational Maturity: The therapeutic implications for human MS remain to be validated in clinical settings, as differences in immune regulation and disease dynamics may limit direct extrapolation.

Nevertheless, the study establishes a strong molecular rationale for further exploration of PARP7 as a modulator of autoimmunity and neuroinflammation, with potential applicability to other autoimmune disease models.

Protocol Parameters

• EAE Induction: MOG (35-55) peptide is administered subcutaneously at 50–150 μg per mouse, emulsified in complete Freund's adjuvant (CFA), as established for robust EAE induction (internal protocol).
• PARP7 Inhibition: Initiate PARP7 inhibitor dosing at the onset or peak of EAE symptoms, following validated dosing schedules from recent studies (see Xu et al., 2025 for experimental details).
• Monitoring Disease Progression: Employ daily neurological scoring and post-mortem histopathology to assess demyelination and immune infiltration.
• In Vitro Assays: For mechanistic studies, consider 0–50 μg/mL MOG (35-55) peptide in cell-based assays with 48-hour incubation, as recommended in product guidelines.

Research Support Resources

To replicate or extend these workflows, researchers require a reliable source of myelin oligodendrocyte glycoprotein peptide for EAE induction and in vitro immune assays. MOG (35-55) Peptide (SKU A8306) from APExBIO is widely adopted in multiple sclerosis research for its high purity and reproducibility. For protocol optimization and troubleshooting, consult the referenced internal articles for EAE induction and neuroinflammation assay best practices. Integrating these resources can support rigorous, translationally relevant autoimmune encephalomyelitis research.